News

According to the company, the Sprinter Legend (semicompliant) balloon catheter provides the latest innovations in balloon technology and is well equipped to address difficult lesions in coronary angioplasty

According to the company, significant positive results were achieved, clearly demonstrating the efficacy and safety of this simple, low-cost method to reduce pain within the first few days

Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with

The trial was conducted in 16 healthy volunteers to evaluate the safety and pharmacologic effect of PCI-27483. A single administration of PCI-27483 resulted in a linear dose response

The patent stems from a provisional patent application filed in the US Patent & Trademark Office (USPTO) in 2000 by the University of Melbourne. In 2007, MorphoSys signed

Under the terms of the merger agreement, King’s tender offer for all of the outstanding shares of class A common stock of Alpharma will be extended and will

Under the terms of the agreement, Johnson & Johnson (J&J) will commence a tender offer to purchase all outstanding shares of Omrix at $25 per share, which is

The alliance spans all activities from target discovery through to completion of proof of concept clinical trials of novel therapeutic antibodies. Both companies will contribute their core technologies

Under the terms of the collaboration agreement between the two companies, which became effective in January 2007, the selection of XL413 by Bristol-Myers Squibb entitles Exelixis to a